AUC

:   area under the curve

BMI

:   body mass index

CI

:   confidence interval

QUADAS

:   Quality Assessment of Diagnostic Accuracy Studies

SWE

:   shear wave elastography

2D

:   2‐dimensional

Hepatic fibrosis is the repair response and healing process of liver injury caused by chronic liver diseases, leading finally to cirrhosis.[1](#jum14760-bib-0001){ref-type="ref"} And the risk of hepatocellular carcinoma increases according to the stage of liver fibrosis.[2](#jum14760-bib-0002){ref-type="ref"} There are multiple causes of chronic liver disease including hepatitis B, hepatitis C, non‐alcoholic fatty liver disease and alcoholic liver disease.[3](#jum14760-bib-0003){ref-type="ref"} A precise estimation of the severity of liver fibrosis and a valid diagnosis of cirrhosis are important steps for determining the prognosis and planning treatment for patients with chronic liver diseases. Liver biopsy has been considered the standard of reference for the evaluation of liver fibrosis. However, it has some limitations, including its invasive nature, incidence of sampling errors, intra‐ and inter‐observer variability and expense.[4](#jum14760-bib-0004){ref-type="ref"}, [5](#jum14760-bib-0005){ref-type="ref"}

In recent years, research has focused on the evaluation of noninvasive methods for the assessment of liver fibrosis, and various ultrasound‐based elastographic methods have enabled noninvasive, economical, and quantitative measurement of liver stiffness, including transient elastography, point shear wave elastography (SWE), and 2‐dimensional (2D) SWE.[6](#jum14760-bib-0006){ref-type="ref"}, [7](#jum14760-bib-0007){ref-type="ref"}, [8](#jum14760-bib-0008){ref-type="ref"} Two‐dimensional SWE, based on supersonic shear imaging, is a novel elastographic technique among these methods.[9](#jum14760-bib-0009){ref-type="ref"} It can be conveniently performed with the use of an ultrasound scanner and can create a real‐time 2D quantitative map of liver tissue stiffness under the guidance of very high--frame rate B‐mode imaging.[10](#jum14760-bib-0010){ref-type="ref"} In addition 2D SWE can assess the homogeneity of the liver because it produces color images corresponding to the varying degrees of hardness. Two‐dimensional SWE could represent an alternative method to transient elastography and point SWE for the noninvasive assessment of liver fibrosis.

Two‐dimensional SWE has proven to be efficient for the evaluation of liver fibrosis in several small to moderate‐size trials. In this study, we performed a meta‐analysis to assess the overall performance of 2D SWE for the diagnosis of liver fibrosis, including all relevant publications.

Materials and Methods {#jum14760-sec-0006}
=====================

*Inclusion and Exclusion Criteria* {#jum14760-sec-0007}
----------------------------------

Studies were included if they met each of the following criteria: (1) they evaluated the performance of 2D SWE for the staging of liver fibrosis in adults; (2) the diagnosis of liver fibrosis was made with liver biopsy as the reference standard; (3) the studies used METAVIR[11](#jum14760-bib-0011){ref-type="ref"} as a comparable liver biopsy staging system; and (4) necessary data were provided to extract the true‐positive, false‐positive, true‐negative, and false‐negative results or studies with available data to construct 2 × 2 contingency tables. Exclusion criteria were as follows: (1) animal studies; (2) duplicate publications; and (3) reviews, letters, and editorials.

*Literature Search and Data Extraction* {#jum14760-sec-0008}
---------------------------------------

Two authors independently performed a systematic literature search in both the Web of Science and PubMed for original English‐language articles from January 2000 to September 2017. The search was performed with the following key words: "elastography and liver," "shear wave elastography," "2D SWE," and "liver fibrosis or hepatic fibrosis." We also scanned the references of potentially eligible articles. Any discrepancies between the researchers were resolved by an additional author. The data extraction form included the following: first author, year of publication, country or region of origin, sample size, number of male and female patients, mean age, body mass index (BMI), etiology of liver disease, cutoff stage used, and true‐positive, false‐positive, true‐negative, and false‐negative results from 2D SWE for each fibrosis stage. All analyses were based on previously published studies; thus, no ethical approval and patient consent were required.

*Quality Assessment* {#jum14760-sec-0009}
--------------------

To assess the quality of the included studies, the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS‐2) questionnaire was used.[12](#jum14760-bib-0012){ref-type="ref"} Each study\'s risks of bias and concern for applicability were rated as low, high, or unclear for each domain (assessment of applicability was not applied in the domain of flow and timing).

*Analysis* {#jum14760-sec-0010}
----------

According to the METAVIR scoring system, liver fibrosis was staged into 5 groups: F0, no fibrosis; F1, portal fibrosis without septa; F2, portal fibrosis and few septa; F3, numerous septa without cirrhosis; and F4, cirrhosis. Then, the estimations of the diagnostic accuracy of F0 versus F1--4, F0/1 versus F2--4, F0--2 versus F3--4, and F0--3 versus F4 were described as F≥1, F≥2, F≥3, and F=4.

We used a bivariate hierarchical model to pool the sensitivities, specificities, and summary receiver operating characteristic curves and to estimate the 95% confidence intervals (CIs) for each hepatic fibrosis.[13](#jum14760-bib-0013){ref-type="ref"}, [14](#jum14760-bib-0014){ref-type="ref"} The *I* [2](#jum14760-bib-0002){ref-type="ref"} statistic and *Q* test were used to assess heterogeneity across individual studies. *I* [2](#jum14760-bib-0002){ref-type="ref"} values of less than 25%, 25% to 50%, and greater than 50% indicate low, moderate, and high heterogeneity, respectively. Because only 10 studies were included in the main analysis, we only tested 3 moderator variables to assess whether they could explain the heterogeneity among studies. The 3 moderators were the following: (1) the presence of a control group (whether the study included healthy volunteers); (2) composition of etiology (all or most of the patients in the studies with hepatitis B virus infection or another etiology); and (3) mean BMI.

The risk of a publication bias was examined by construction of a funnel plot of the logarithm odds ratios versus their inverse standard errors. Egger tests were conducted to measure the degree of funnel plot asymmetry.[15](#jum14760-bib-0015){ref-type="ref"}

The quality assessment was made by Review Manager version 5.3 (The Cochrane Collaboration, Copenhagen, Denmark; 2014). All other analyses were performed with R version 3.4.2 (R Foundation for Statistical Computing, Vienna, Austria), particularly the R meta4diag package by Jingyi Guo and Andrea Riebler (version 2.0.5,05.07.2016).

Results {#jum14760-sec-0011}
=======

*Study Selection and Assessment* {#jum14760-sec-0012}
--------------------------------

The study selection process is illustrated in Figure [1](#jum14760-fig-0001){ref-type="fig"}. The initial search yielded 160 articles, 16 of which were excluded because of duplication. The remaining 144 articles were screened by title and abstract; of these, 86 studies were unrelated to the topic; 12 studies were review articles; 14 conference abstracts had insufficient data, and we failed to obtain them from the corresponding authors via e‐mail; and 7 were animal studies. A total of 119 studies were excluded finally. After a detailed review of these articles, 10 full‐text articles were finally included.[16](#jum14760-bib-0016){ref-type="ref"}, [17](#jum14760-bib-0017){ref-type="ref"}, [18](#jum14760-bib-0018){ref-type="ref"}, [19](#jum14760-bib-0019){ref-type="ref"}, [20](#jum14760-bib-0020){ref-type="ref"}, [21](#jum14760-bib-0021){ref-type="ref"}, [22](#jum14760-bib-0022){ref-type="ref"}, [23](#jum14760-bib-0023){ref-type="ref"}, [24](#jum14760-bib-0024){ref-type="ref"}, [25](#jum14760-bib-0025){ref-type="ref"} The quality of the included articles as assessed according to the QUADAS‐2 criteria is reported in Table [1](#jum14760-tbl-0001){ref-type="table"}.

![Flow diagram of the study selection procedure.](JUM-38-733-g001){#jum14760-fig-0001}

###### 

Risk of Bias and Concerns Regarding the Applicability of the Studies in the Analysis (QUADAS‐2)

                                                                   Risk of Bias   Applicability Concerns                   
  --------------------------------------------------------- ------ -------------- ------------------------ --- --- --- --- ---
  Bende et al[16](#jum14760-bib-0016){ref-type="ref"}       2017   H              H                        H   L   L   L   L
  Bota et al[17](#jum14760-bib-0017){ref-type="ref"}        2015   L              H                        H   L   L   H   H
  Ferraioli et al[18](#jum14760-bib-0018){ref-type="ref"}   2012   L              H                        L   L   L   L   L
  Guibal et al[19](#jum14760-bib-0019){ref-type="ref"}      2015   L              H                        L   L   L   L   L
  Leung et al[20](#jum14760-bib-0020){ref-type="ref"}       2013   H              H                        L   H   L   L   L
  Paul et al[21](#jum14760-bib-0021){ref-type="ref"}        2017   L              H                        L   L   L   L   L
  Samir et al[22](#jum14760-bib-0022){ref-type="ref"}       2015   L              H                        L   L   L   L   H
  Sporea et al[23](#jum14760-bib-0023){ref-type="ref"}      2014   H              H                        L   L   L   L   L
  Zeng et al[24](#jum14760-bib-0024){ref-type="ref"}        2017   L              H                        L   ?   L   L   L
  Zheng et al[25](#jum14760-bib-0025){ref-type="ref"}       2015   L              H                        L   H   L   L   L

L indicates low risk; H, high risk; and ?, unclear risk.

*Data Synthesis and Analysis* {#jum14760-sec-0013}
-----------------------------

The patient characteristics for each study are summarized in Table [2](#jum14760-tbl-0002){ref-type="table"}. Ten studies with a total of 2083 patients were included in the meta‐analysis. The numbers of studies discriminating F≥1, F≥2, F≥3, and F=4 were 3, 10, 9, and 10, respectively. Therefore, we did not synthesize the data for the classification of F≥1 because of the small sample size.

###### 

Characteristics of Included Studies

  Study                                                     Year   Country         n     n for Analysis   Male, %   Mean Age, y   Liver Disease      Fibrosis Cutoff Stage[a](#jum14760-note-0003){ref-type="fn"}
  --------------------------------------------------------- ------ --------------- ----- ---------------- --------- ------------- ------------------ --------------------------------------------------------------
  Bende et al[16](#jum14760-bib-0016){ref-type="ref"}       2017   Romania         331   317              38.4      55            CHC, CHB, other    F≥2, F≥3, F=4
  Bota et al[17](#jum14760-bib-0017){ref-type="ref"}        2015   Austria         126   94               50.4      52.7 ± 13.3   CHC, CHB, others   F≥2, F≥3, F=4
  Ferraioli et al[18](#jum14760-bib-0018){ref-type="ref"}   2012   Italy           121   118              87        44.8 ± 11.9   CHC                F≥2, F≥3, F=4
  Guibal et al[19](#jum14760-bib-0019){ref-type="ref"}      2015   France          170   148              64.2      54.3 ± 13.2   NASH, CHB, other   F≥2, F≥3, F=4
  Leung et al[20](#jum14760-bib-0020){ref-type="ref"}       2013   Hong Kong       454   226              65        48.8 ± 12.3   CHB                F≥1, F≥2, F≥3, F=4
  Paul et al[21](#jum14760-bib-0021){ref-type="ref"}        2017   India           256   237              73.3      32.6 ± 11.6   CHB, CHC           F≥1, F≥2, F≥3, F=4
  Samir et al[22](#jum14760-bib-0022){ref-type="ref"}       2015   United States   138   136              51.4      49            CHC, CHB, other    F≥2, F≥3, F=4
  Sporea et al[23](#jum14760-bib-0023){ref-type="ref"}      2014   Romania         383   250              45.9      54            CHC, CHB, other    F≥1, F≥2, F≥3, F=4
  Zeng et al[24](#jum14760-bib-0024){ref-type="ref"}        2017   China           257   235              77.4      36.7 ± 9.4    CHB                F≥2, F≥3, F=4
  Zheng et al[25](#jum14760-bib-0025){ref-type="ref"}       2015   China           200   167              71.2      37.7          CHC, CHB, other    F≥2, F=4

Data are presented as mean ± SD where applicable. CHB indicates chronic hepatitis B; CHC, chronic hepatitis C; and NASH, nonalcoholic steatohepatitis.

Cutoff stage for fibrosis used for the construction of a 2 × 2 contingency table.

Figure [2](#jum14760-fig-0002){ref-type="fig"} shows forest plots of summary sensitivities and specificities. For each stage, discrimination in the bivariate meta‐analysis led to summary sensitivities of 0.85 (95% CI, 0.80--0.89), 0.90 (95% CI, 0.87--0.93), and 0.89 (95% CI, 0.84--0.93) for F≥2, F≥3, and F=4, respectively. Similarly, the summary specificities for F≥2, F≥3, and F=4 were 0.79 (95% CI, 0.72--0.85), 0.85 (95% CI, 0.80--0.89), and 0.92 (95% CI, 0.89--0.95). The summary receiver operating characteristic curves for F≥2, F≥3, and F=4 are shown in Figure [3](#jum14760-fig-0003){ref-type="fig"}. The areas under the curves (AUCs) for F≥2, F≥3, and F=4 were 0.81, 0.77, and 0.84. The *I* [2](#jum14760-bib-0002){ref-type="ref"} values of the test results for F≥2, F≥3, and F=4 were 74.27%, 84.08%, and 78.61%, indicating that the heterogeneity was significant among studies. The mean BMI, presence of a control group, and disease type did not significantly explain the heterogeneity for each stage.

![Forest plots of sensitivity and specificity for F≥2 (**A**), F≥3 (**B**), and F=4 (**C**).](JUM-38-733-g002){#jum14760-fig-0002}

![Summary receiver operating characteristic (SROC) curves for F≥2, F≥3, and F=4. The 95% confidence regions and prediction regions are shown.](JUM-38-733-g003){#jum14760-fig-0003}

*Publication Bias* {#jum14760-sec-0014}
------------------

The funnel plot asymmetry tests for each fibrosis stage are shown in Figure [4](#jum14760-fig-0004){ref-type="fig"}. The *P* values from the asymmetry test (Egger test) were as follows: *P* = .0343 for F≥2, *P* \< .0001 for F≥3, and *P* = .0015 for F=4; a potential publication bias was likely present.

![Funnel plots according to F≥2, F≥3, and F=4. The points represent studies included in the meta‐analysis.](JUM-38-733-g004){#jum14760-fig-0004}

Discussion {#jum14760-sec-0015}
==========

This study evaluated the diagnostic performance of 2D SWE for the staging of liver fibrosis, and 10 full‐text studies were included: 2 studies including patients infected with chronic hepatitis B,[20](#jum14760-bib-0020){ref-type="ref"}, [24](#jum14760-bib-0024){ref-type="ref"}, 1 study including patients infected with chronic hepatitis C,[18](#jum14760-bib-0018){ref-type="ref"} and 7 studies pooling patients with different chronic liver diseases.[16](#jum14760-bib-0016){ref-type="ref"}, [17](#jum14760-bib-0017){ref-type="ref"}, [19](#jum14760-bib-0019){ref-type="ref"}, [21](#jum14760-bib-0021){ref-type="ref"}, [22](#jum14760-bib-0022){ref-type="ref"}, [23](#jum14760-bib-0023){ref-type="ref"}, [25](#jum14760-bib-0025){ref-type="ref"} The results of our meta‐analysis demonstrated that 2D SWE gave good diagnostic accuracy for detection of liver cirrhosis (F=4) and substantial fibrosis (F≥2), with pooled sensitivity of 0.89, specificity of 0.92, and AUC of 0.84 for F=4 and sensitivity of 0.85, specificity of 0.79, and AUC of 0.81 for F≥2. However, it was not highly accurate for diagnosis of severe fibrosis (F≥3) with an AUC of 0.77. Our results are partly in accordance with the results of a previous meta‐analysis,[26](#jum14760-bib-0026){ref-type="ref"} which reported diagnostic accuracies of 0.86, 0.90, and 0.93 for F≥2, F≥3, and F=4, respectively; however, the number of patients included in our meta‐analysis was almost twice that of the previous study. Thus, the performances of both meta‐analyses confirmed the diagnostic accuracy for liver cirrhosis and substantial fibrosis. With the use of a pretest probability of 50%, 2D SWE had high posttest probabilities of 80.1%, 85.7%, and 91.8% for substantial fibrosis, severe fibrosis, and liver cirrhosis, respectively.

A comparable meta‐analysis of SWE revealed overall diagnostic accuracies of 0.93 for the diagnosis of liver cirrhosis, 0.93 for the diagnosis of severe fibrosis, and 0.85 for the diagnosis of substantial fibrosis, encompassing 2 of the SWE technologies: point SWE and 2D SWE.[27](#jum14760-bib-0027){ref-type="ref"} However, the studies in our meta‐analysis only included 2D SWE technology. Two‐dimensional SWE has been proven to be efficient for the evaluation of liver fibrosis in several studies, reporting equivalent to superior diagnostic accuracies compared to point SWE for the assessment of liver fibrosis.[18](#jum14760-bib-0018){ref-type="ref"}, [19](#jum14760-bib-0019){ref-type="ref"}, [28](#jum14760-bib-0028){ref-type="ref"}, [29](#jum14760-bib-0029){ref-type="ref"} Two‐dimensional SWE produced a shear wave that spread less and thus decayed less rapidly with distance than that of a single pushing focus in point SWE. Two‐dimensional SWE can create a real‐time 2D quantitative map of liver tissue under the guidance of very high--frame rate B‐mode imaging.[6](#jum14760-bib-0006){ref-type="ref"}

A previous meta‐analysis evaluating point SWE including patients with mixed chronic liver diseases reported accuracies of 0.84 for the diagnosis of substantial fibrosis, 0.89 for the diagnosis of severe fibrosis, and 0.91 for the diagnosis of liver cirrhosis.[30](#jum14760-bib-0030){ref-type="ref"} A recent study reported that 2D SWE showed a better correlation compared to point SWE in a pediatric population.[31](#jum14760-bib-0031){ref-type="ref"} The advantage of 2D SWE is highlighted by the fact that this ultrasound‐based elastographic method is integrated in an ultrasound machine that can be used for other examinations.[25](#jum14760-bib-0025){ref-type="ref"} As a new method, 2D SWE has the following advantages compared to acoustic radiation force impulse imaging: qualitative (color coded) and quantitative measurement, easier and more manageable measurement, and stability of the measured value.[18](#jum14760-bib-0018){ref-type="ref"}, [31](#jum14760-bib-0031){ref-type="ref"} However, 2D SWE has some limitations, such as the subjective nature of the color scale and a potential bias when selecting the region of interest.

Our assessment of the included studies according to QUADAS‐2 showed that most of the studies\' index tests were judged to have a high risk of bias because they did not use prespecified cutoff values. In contrast, most studies used an acceptable method to stage liver fibrosis based on liver biopsy. Some studies were assessed to be at a high risk of bias for patient selection.

Our analysis had several limitations. First, significant heterogeneity and a publication bias were found among the individual studies for all fibrosis stages. The heterogeneity had multiple sources. In this analysis, heterogeneity may come from the difference of the sampling protocol, biopsy protocol, machine, or software used for measurement in the studies or a combination of these factors. Meanwhile, the accuracy of 2D SWE mainly relies on the operator\'s performance. We assessed only the reasons for different BMIs in patients, studies including a control group or not, and studies with patients infected with hepatitis B virus, hepatitis C virus, or mixed disease. The sensitivity analysis indicated that the different mean BMIs, control group inclusion, and disease type did not significantly explain the heterogeneity for each stage. Due to the small sizes of the included studies, we did not analyze other probable sources. Second, the cutoff values for diagnosing F2, F3, and F4 fibrosis ranged from 6.0 to 18.1 kPa in the different studies. However, we could not perform a subgroup analysis to obtain a single cutoff value because of the limited number of studies, and this factor needs to be confirmed by an analysis including a larger number of studies.

In conclusion, 2D SWE is a good noninvasive method for the diagnosis of substantial liver fibrosis and cirrhosis. It is a promising screening tool for integration into routine imaging protocols for the staging of liver fibrosis and cirrhosis. Further studies with large sample sizes are needed to assess severe fibrosis and perform head‐to‐head comparisons of 2D SWE with other noninvasive techniques for the evaluation of liver fibrosis.
